Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Daily News

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

Michael O'Riordan

December 19, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Statin Use Has Plateaued in US Primary Prevention Patients

Michael O'Riordan

December 05, 2023

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Daily News

Very High LDL Cholesterol Declines in US Adults, but Progress Is Slow

Michael O'Riordan

November 02, 2023

News Daily News

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

Michael O'Riordan

September 14, 2023

News Daily News

USPSTF: Screening Kids for Lipid Disorders Still Needs More Data

Shelley Wood

July 18, 2023

News Daily News

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Michael O'Riordan

July 07, 2023

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

News Conference News EAS 2023

Multipronged Outreach to Families Can Boost FH Cascade Screening: IMPACT-FH

Michael O'Riordan

May 26, 2023

News Conference News EAS 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Michael O'Riordan

May 24, 2023

News Conference News EAS 2023

High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture

Michael O'Riordan

May 23, 2023

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Todd Neale

March 10, 2023

News Conference News ACC 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Shelley Wood

March 08, 2023

Presentation ACC 2023

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Presenter: Christie Ballantyne

March 05, 2023

Advertisement

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Statin Use Has Plateaued in US Primary Prevention Patients

Mortality Risk Varies Among Patients With Very High LDL Levels

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

What’s Going to Be Hot at AHA 2023

Very High LDL Cholesterol Declines in US Adults, but Progress Is Slow

Evinacumab Helps Severe Hypercholesterolemia Patients Reach LDL Targets

USPSTF: Screening Kids for Lipid Disorders Still Needs More Data

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Multipronged Outreach to Families Can Boost FH Cascade Screening: IMPACT-FH

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content